Format

Send to

Choose Destination
Indian J Nucl Med. 2019 Apr-Jun;34(2):150-152. doi: 10.4103/ijnm.IJNM_28_19.

Advantages of the 99mTc-sestamibi Single-Photon Emission Computed Tomography/Computed Tomography in Occult Parathyroid Adenoma and Concomitant Thyroid Papillary Carcinoma.

Author information

1
Department of Otorhinolaryngology and Head and Neck, Clínica de Marly, Colombia.
2
Department of Otorhinolaryngology, Universidad Nacional de Colombia, Bogotá D.C., Colombia.
3
Department of Head and Neck, Instituto Nacional de Cancerología, , Bogotá D.C., Colombia.
4
Department of Nuclear Medicine, Instituto Nacional de Cancerología, Bogotá D.C, Colombia.
5
Department of Pathology, Clínica de Marly, Bogotá D.C, Colombia.

Abstract

Hyperparathyroidism and concurrent thyroid nodular disease are prominent. In contrast, concomitant papillary thyroid cancer and hyperparathyroidism are uncommon (1%-2%). Parathyroid adenomas in unusual locations are difficult to detect by conventional diagnostic imaging. 99mTc-sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) has increased the localizing success rate of these lesions since it provides specific functional and anatomical information, improving exploratory parathyroid surgery planning and decreasing operative time, unnecessary dissections, complications, and morbidity. We confirmed its usefulness in a patient with an occult parathyroid adenoma that was clearly identified by 99mTc-sestamibi SPECT/CT 2 weeks after a thyroidectomy for papillary carcinoma. The SPECT/CT results allowed us to successfully perform efficient reexploration of the thyroid bed, in a retroesophageal parathyroid adenoma by minimally invasive surgery.

KEYWORDS:

Hypercalcemia; hyperparathyroidism; minimally invasive surgical procedures; reoperation; single-photon emission computed tomography/computed tomography

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center